Collegium Pharmaceutical Inc. (COLL) Trading Down 3.2%
Collegium Pharmaceutical Inc. (NASDAQ:COLL) dropped 3.2% on Thursday . The company traded as low as $11.99 and last traded at $12.00, with a volume of 59,884 shares traded. The stock had previously closed at $12.40.
COLL has been the subject of a number of research reports. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, July 6th. Needham & Company LLC reissued a “buy” rating and set a $30.00 target price (up previously from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $26.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $29.25.
The company’s market cap is $283.27 million. The company has a 50-day moving average price of $12.51 and a 200 day moving average price of $16.26.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.08. On average, equities analysts expect that Collegium Pharmaceutical Inc. will post ($3.25) EPS for the current fiscal year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.